Vertex Pharmaceuticals Stock Is Approaching a Huge Catalyst, But Is It a Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) shareholders know just how good it can be to ride a biopharma stock upward as it notches positive milestones year after year. With its shares up by 99% in the last three years alone, one would be forgiven for expecting that this company is going to be slowing down for a while.
But, as it turns out, another massive catalyst is probably right around the corner, and it could make the other recent accomplishments look trivial in terms of the financial effect. Here's what you need to know about what's going on and how it'll affect your decision about whether to invest in the stock.
On Jan. 30, Vertex reported the results from its two phase 3 clinical trials of VX-548, a painkiller intended for treating moderate to severe pain. While the trials met their primary endpoint, which was to significantly reduce the pain experienced by patients after receiving abdominoplasty surgery or bunionectomy surgery beyond what might be possible with a placebo, they were not a total success.
Source Fool.com
Vertex Pharmaceuticals Inc. Aktie
Vertex Pharmaceuticals Inc. ist ein klarer Community-Favorit mit mehr Buy- als Sell-Einschätzungen.
Trotz eines Kursziels von 440 €, das unter 452.65 € liegt, ergibt sich für Vertex Pharmaceuticals Inc. ein negatives Potenzial von -2.79%.
